Cardiol Therapeutics Inc.

Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results for CardiolRx™ in recurrent pericarditis in the Journal of the American Heart Association (JAHA). The study demonstrated rapid and sustained reductions in pain and inflammation, substantial reductions in pericarditis episodes, and a favorable safety profile. This publication strengthens the clinical rationale for the ongoing pivotal Phase III MAVERIC trial, which is nearing full patient enrollment.

Cardiol Therapeutics Inc. announced its participation in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit. The event is scheduled for July 16, 2026, at 12:20 p.m. EDT, in Boston. The company, a late-stage life sciences firm, focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead candidate CardiolRx™ in pivotal trials.

Cardiol Therapeutics Inc. announced the results of its Annual General Meeting of Shareholders (AGM) held virtually on June 24, 2026. Shareholders voted overwhelmingly in favour of all Management resolutions. This included the election of eight directors for the upcoming year and the re-appointment of BDO Canada LLP as the Company's auditors.

Cardiol Therapeutics Inc. announced it will webcast its virtual Annual General Meeting of Shareholders on June 24th at 4:30 PM EDT. The company, a late-stage life sciences firm, is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, currently in a pivotal Phase III trial for recurrent pericarditis. CardiolRx™ has received U.S. FDA Orphan Drug Designation for pericarditis, and the company is also developing CRD-38 for inflammatory heart disease.

Cardiol Therapeutics Inc. announced its Annual General Meeting (AGM) of shareholders will be held virtually on June 24, 2026, at 4:30 p.m. EDT. Shareholders will vote on receiving 2025 financial statements, electing directors, and appointing BDO Canada LLP as auditors for 2026. The company is utilizing a notice-and-access mechanism for distributing meeting materials electronically.

Cardiol Therapeutics Inc. announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference. The company will host a Fireside Chat on May 19, 2026, at 1:30 p.m. EDT, which will be accessible via live webcast on its investor relations website. Cardiol Therapeutics is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease, with lead drug candidate CardiolRx™ in Phase III for recurrent pericarditis and CRD-38 in development.

Cardiol Therapeutics reported a net loss of $(10.8) million for Q1 2026, an increase from $(8.29) million in Q1 2025, driven by higher research and development expenses and a loss from derivative liability revaluation. Despite the increased loss, basic and diluted net loss per share remained $(0.10) due to a significant increase in outstanding shares. The company bolstered its financial position by completing a unit financing in January 2026, generating $14.85 million in gross proceeds.

Cardiol Therapeutics announced that the results from its Phase II MAvERIC study, evaluating CardiolRx in patients with recurrent pericarditis, have been accepted for publication in the Journal of the American Heart Association (JAHA). The study demonstrated that CardiolRx was associated with rapid and sustained reductions in pericarditis pain and inflammation, along with a substantial reduction in pericarditis episodes per year and a favorable safety profile. These findings provide important clinical validation for the ongoing pivotal Phase III MAVERIC trial, which has now surpassed 75% enrollment.

Cardiol Therapeutics Inc. announced the expansion of its U.S. MAVERIC Phase III clinical trial network. This expansion is in response to growing interest in the pivotal program, which is evaluating CardiolRx for the treatment of acute myocarditis. The trial aims to reduce major cardiovascular events in patients with this serious inflammatory heart condition.